Gritgen Therapeutics Co., a biotechnology company focused on gene therapy products, reported the successful validation and launch of operations at its commercial GMP facility in Suzhou China for the production of Gritgen’s phase III clinical and commercial product for hemophilia A. The construction of Gritgen’s GMP facility adheres to the global cGMP standards and complies with the regulatory guidelines of authoritative agencies including the NMPA, the FDA and the EMA. The 8,600 s...